department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

News

when

Latest
Archive

by source

All Sources
Sources Page

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

made by humans and a good dog

home
jobs
news
search

calendar

41 catalysts · 8 phase 2 completion · 7 patent expiry · 6 phase 1 completion · 4 phase 1 initiation · 4 phase 2 initiation · 3 constraining patent expiry europe

★ save view ↓export CSV

next 91 dayslessmore

MonWedFri

view

agenda month

show past →

sort

soonest latest type sponsor alpha

TA: infectious-disease×clear all

type

phase 2 completion8
patent expiry7
phase 1 completion6
phase 1 initiation4
phase 2 initiation4
constraining patent expiry europe3

drug expiry3

phase 3 completion3

pdufa1

phase iv trial initiation1

therapy area

Oncology139
Infectious Disease41
Cardiology37
Immunology32
Dermatology27
Pulmonology19
Women's Health16
Ophthalmology15
Pain12

Week of Apr 20, 2026

›Apr 25, 2026phase 1 completion90d agoChangchun Bcht Biotechnology Co Ltd — influenza (trivalent, split virion) vaccine (Phase I Trial Completion)influenza (trivalent, split virion) vaccine

Therapy area: Infectious Disease. Indication: Unspecified Influenza Virus Infections

full page →influenza (trivalent, split virion) vaccine →source: globaldata

›Apr 25, 2026phase 2 completion90d agoTamilnadu Government Dental College and Hospital — Gengigel (Phase II Trial Completion)Gengigel

Therapy area: Infectious Disease. Indication: Dental Abscess

full page →Gengigel →source: globaldata

›Apr 25, 2026phase 2 initiation90d agoGSK plc — dostarlimab (Phase II Trial Initiation)dostarlimab

Therapy area: Infectious Disease. Indication: Hepatitis B

full page →dostarlimab →source: globaldata

›Apr 26, 2026phase 2 completion89d agoBangalore Medical College and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

Therapy area: Infectious Disease, Women's Health. Indication: Labor And Delivery, Pregnancy, Puerperal Infection

full page →bupivacaine →source: globaldata

›Apr 26, 2026phase 3 completion89d agoHubei Provincial Center for Disease Control and Prevention — rabies vaccine (Phase III Trial Completion)rabies vaccine

Therapy area: Infectious Disease. Indication: Rabies

full page →rabies vaccine →source: globaldata

Week of Apr 27, 2026

›Apr 27, 2026phase 1 initiation88d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

full page →pembrolizumab →source: globaldata

›Apr 27, 2026constraining patent expiry europe

88d ago

Bill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Europe))SB-692342

Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

full page →SB-692342 →source: globaldata

›Apr 27, 2026patent expiry88d agoBill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Japan))SB-692342

Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

full page →SB-692342 →source: globaldata

›Apr 27, 2026phase 2 completion88d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

Therapy area: Infectious Disease. Indication: Salmonella Infections

full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata

›Apr 27, 2026phase 2 initiation88d agoNational Institute of Neurological Disorders and Stroke — brincidofovir (Phase II Trial Initiation)brincidofovir

Therapy area: Infectious Disease. Indication: Progressive Multifocal Leukoencephalopathy

full page →brincidofovir →source: globaldata

›Apr 27, 2026phase 3 completion88d agoSanofi — meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) (Phase III Trial Completion)meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi)

Therapy area: Infectious Disease. Indication: Neisseria meningitidis Infections

full page →meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) →source: globaldata

›Apr 27, 2026phase iv trial initiation88d agoAll India Institute of Medical Sciences Patna — typhoid Vi polysaccharide vaccine (Phase IV Trial Initiation)typhoid Vi polysaccharide vaccine

Therapy area: Infectious Disease. Indication: Typhoid Fever

full page →typhoid Vi polysaccharide vaccine →source: globaldata

›Apr 28, 2026constraining patent expiry europe87d agoLupin Ltd — (dolutegravir + lamivudine + tenofovir disoproxil fumarate) (Constraining Patent Expiry (Europe))(dolutegravir + lamivudine + tenofovir disoproxil fumarate)

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →(dolutegravir + lamivudine + tenofovir disoproxil fumarate) →source: globaldata

›Apr 28, 2026patent expiry87d agoGSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →dolutegravir sodium →source: globaldata

›Apr 28, 2026patent expiry87d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata

›Apr 28, 2026patent expiry87d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir sodium →source: globaldata

›Apr 28, 2026patent expiry87d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir + rilpivirine LA →source: globaldata

›Apr 28, 2026patent expiry87d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir LA →source: globaldata

›Apr 28, 2026drug expiry87d agoGSK plc — cabotegravir sodium (Drug Expiry (US))cabotegravir sodium

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir sodium →source: globaldata

›Apr 28, 2026drug expiry87d agoViiV Healthcare UK Ltd — cabotegravir LA (Drug Expiry (US))cabotegravir LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir LA →source: globaldata

›Apr 28, 2026drug expiry87d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Drug Expiry (US))cabotegravir + rilpivirine LA

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →cabotegravir + rilpivirine LA →source: globaldata

›Apr 28, 2026pdufa87d agoMerck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)(doravirine + islatravir hydrate)

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →(doravirine + islatravir hydrate) →source: globaldata

›Apr 28, 2026phase 1 completion87d agoGSK plc — bepirovirsen sodium (Phase I Trial Completion)bepirovirsen sodium

Therapy area: Infectious Disease. Indication: Hepatitis B

full page →bepirovirsen sodium →source: globaldata

›Apr 28, 2026phase 1 completion87d agoBio-Innova Co Ltd — clarithromycin (Phase I Trial Completion)clarithromycin

Therapy area: Central Nervous System, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Genito Urinary System, Infectious Disease, Mouth and Dental Disorders, Respiratory. Indication: Abscess, Acne Vulgaris, Acute Bacterial Sinusitis, Acute Bronchitis, Acute Pharyngitis, Bacterial Pneumonia, Bacterial Respiratory Tract Infections, Bartonella Infections, Bronchitis, Carbuncle, Cellulitis, Chlamydia trachomatis Pneumonia, Chronic Bronchitis, Community Acquired Pneumonia, Community-Acquired

full page →clarithromycin →source: globaldata

›Apr 28, 2026phase 3 completion87d agoGovernment Stanley Medical College Hospital — tenecteplase (Phase III Trial Completion)tenecteplase

Therapy area: Genito Urinary System, Infectious Disease. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Unspecified Bacterial Infections

full page →tenecteplase →source: globaldata

›Apr 29, 2026phase 1 initiation86d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

full page →adenovirus vector (spike protein) vaccine →source: globaldata

›Apr 29, 2026phase 2 completion86d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

full page →(amoxicillin + clavulanic acid) →source: globaldata

›Apr 29, 2026phase 2 initiation86d agoYunpeng Pharmaceutical Co Ltd — norfloxacin (Phase II Trial Initiation)norfloxacin

Therapy area: Gastrointestinal, Genito Urinary System, Infectious Disease. Indication: Gonorrhea, Intestinal Infection, Salmonella Infections, Typhoid Fever, Urinary Tract Infections

full page →norfloxacin →source: globaldata

›Apr 29, 2026phase 2 initiation86d agoHuahui Health Ltd — HH-006 (Phase II Trial Initiation)HH-006

Therapy area: Infectious Disease. Indication: Hepatitis B

full page →HH-006 →source: globaldata

›Apr 30, 2026constraining patent expiry europe85d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

full page →telavancin hydrochloride →source: globaldata

›Apr 30, 2026patent expiry85d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

full page →isavuconazonium sulfate →source: globaldata

›Apr 30, 2026phase 1 completion85d agoShenzhen Digestive System Disease Clinical Medicine Research Center — tegoprazan (Phase I Trial Completion)tegoprazan

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →tegoprazan →source: globaldata

›Apr 30, 2026phase 1 completion85d agoMAXVAX Biotechnology Co Ltd — MKK-900 (Phase I Trial Completion)MKK-900

Therapy area: Infectious Disease. Indication: Respiratory Syncytial Virus (RSV) Infections

full page →MKK-900 →source: globaldata

›Apr 30, 2026phase 1 completion85d agoJohns Hopkins University — ciprofloxacin (Phase I Trial Completion)ciprofloxacin

Therapy area: Infectious Disease. Indication: Bacillary Dysentery (Shigellosis)

full page →ciprofloxacin →source: globaldata

›Apr 30, 2026phase 1 initiation85d agoGilead Sciences Inc — GS-1701 (Phase I Trial Initiation)GS-1701

Therapy area: Infectious Disease. Indication: Unspecified Infectious Diseases

full page →GS-1701 →source: globaldata

›Apr 30, 2026phase 1 initiation85d agoThe National Institute of Allergy and Infectious Diseases — dasatinib (Phase I Trial Initiation)DASATINIB

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →DASATINIB →source: globaldata

›Apr 30, 2026phase 1 2 completion85d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

›Apr 30, 2026phase 2 completion85d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

›Apr 30, 2026phase 2 completion85d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

full page →metformin hydrochloride ER →source: globaldata

›Apr 30, 2026phase 2 completion85d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

›Apr 30, 2026phase 2 completion85d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

full page →Vacucis →source: globaldata

$GSK50.74-0.04%

$OCGN1.2700-1.55%

$MRK130.48+2.36%

$GSK50.74-0.04%

$SNY43.36-0.98%

$GSK50.74-0.04%

$CPIX6.9850-1.83%

$GILD130.86+0.40%